AFFIMED
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
AFFIMED
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2000-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.affimed.com
Total Employee:
51+
Status:
Active
Contact:
+49 (0)6221-6743-60
Email Addresses:
[email protected]
Total Funding:
534.03 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon WordPress Font Awesome Mobile Non Scaleable Content HSTS Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin
Similar Organizations
Agenus
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
bit.bio
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Castor
Castor offers a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
UniQure
uniQure is focused on the research and early development of human gene-based therapies.
Verona Pharma
Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Founder
Stock Details
Investors List
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Affimed
Roche
Roche investment in Post-IPO Equity - Affimed
Aeris Capital
Aeris Capital investment in Post-IPO Equity - Affimed
German Federal Ministry of Education and Research
German Federal Ministry of Education and Research investment in Grant - Affimed
Perceptive Advisors
Perceptive Advisors investment in Debt Financing - Affimed
BioMedPartners
BioMedPartners investment in Series E - Affimed
OrbiMed
OrbiMed investment in Series E - Affimed
Novo Holdings
Novo Holdings investment in Series E - Affimed
Aeris Capital
Aeris Capital investment in Series E - Affimed
EQT Life Sciences
EQT Life Sciences investment in Series E - Affimed
Official Site Inspections
http://www.affimed.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.28 K
- Host name: 217-160-0-75.elastic-ssl.ui-r.com
- IP address: 217.160.0.75
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Affimed"
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Go forward organization will focus on advancing clinical programs; Company confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024; …See details»
Homepage - Affimed
A one-of-a-kind approach for revolutionary outcomes. We are revolutionizing cancer treatment by activating the untapped power of the innate immune system to eradicate tumors. Our novel …See details»
About us - Affimed
Affimed fosters and continues to seek partnerships that align with the company’s overall corporate strategy. Working together, we aim to advance our clinical …See details»
Affimed Announces Leadership Change and Organizational
Jan 8, 2024 Affimed also announced today a restructuring initiative aimed at transforming the Company into a focused clinical organization, positioned to successfully advance its clinical …See details»
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Affimed N.V. Dr. Adi Hoess to step down as CEO and Management Board Member. Dr. Andreas Harstrick appointed Interim CEO. Strategic restructuring reducing headcount by …See details»
Affimed - Crunchbase Company Profile & Funding
Organization. Affimed . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of …See details»
Affimed - LinkedIn
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate ...See details»
Affimed N.V. Announces Accepted Abstracts for Oral and Poster
2 days ago Affimed announces abstract acceptance for ASCO 2025 on cancer treatments acimtamig and AFM24 with positive study results. Quiver AI Summary. Affimed N.V., a clinical …See details»
Affimed Announces Acceptance of Three Abstracts for …
2 days ago Affimed N.V. MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology …See details»
Corporate Governance - Affimed
Leadership. The fundamental element of Affimed’s corporate governance is its two-tier system with a separation of Management Board, responsible for the management of the Company and the general conduct of the Company’s …See details»
Affimed N.V. - Craft
Affimed N.V. has 5 employees at their 1 location and €8.28 m in annual revenue in FY 2023. See insights on Affimed N.V. including office locations, competitors, revenue, financials, …See details»
Affimed Announces Acimtamig and AlloNK® Combination …
Dec 5, 2024 Affimed N.V. Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed …See details»
Affimed (LON:0HL9) Company Profile & Description - Stock Analysis
Mar 28, 2025 Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s …See details»
Affimed’s Promising Clinical Update on NSCLC Treatment
Dec 17, 2024 Affimed N.V. is a clinical-stage immuno-oncology company based in Mannheim, Germany. It focuses on leveraging the innate immune system to combat cancer, utilizing its …See details»
Affimed Announces Positive Results Demonstrating Safety and …
Dec 8, 2024 Affimed Investor Relations Contact. Alexander Fudukidis Director, Investor Relations E-Mail: [email protected] Tel.: +1 (917) 436-8102 Affimed Media Contact. …See details»
AFMD_Corporate Presentation_Jan 2025 - affimed.com
To Affimed of orphan drug designation; the impact on our business by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties, such as the …See details»
Affimed Announces Leadership Change and Organizational …
Jan 8, 2024 Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go forward organization will focus on …See details»
Affimed - Gilde Healthcare
Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer. …See details»
Affimed Announces Receipt of NASDAQ Deficiency Notice
4 days ago Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of …See details»
Investors - Affimed
Affimed was founded in 2000. Where is the company incorporated? Affimed N.V. is incorporated under the laws of the Netherlands. When did Affimed go public? Affimed’s common shares …See details»